Dr Peter Pack, CEO of Crescendo Biologics commented: “Crescendo’s platform is delivering a robust pipeline of intrinsically differentiated, multi-functional therapeutics in the oncology space. As we continue our growth, we look forward to exploring new partnership opportunities that can advance our pipeline and leverage the capabilities of our transgenic platform. A strong and experienced team is key to reaching our ambitions and Tad brings broad experience in business and corporate development as well as organisational growth, making him a great addition to our leadership team as we accelerate the evolution of Crescendo.”
Tad Stewart, the new CBO, added: “Crescendo is developing a very exciting and highly differentiated pipeline of therapeutics. I look forward to joining the team and contributing my experience to advance those products, achieve our corporate goals and realise the full potential of the Humabody platform.”
Tad brings over twenty years of experience working in the biotechnology field. He joins Crescendo from Merrimack Pharmaceuticals, Inc. where he served in several executive roles, including leading the commercial business unit and the business development function.
Tad was one of the first employees of Merrimack and his experience spans the growth of the company from a pre-clinical organisation to a commercial enterprise, comprising of the successful launch of a marketed oncology product and execution of several transactions that supported the long-term growth of the company. Prior to Merrimack, Tad worked across the biotech, pharmaceutical and medical device industries as a consultant.
Tad holds an MBA from the Johnson School at Cornell University and a BS in Biology from Bates College.
